Overview

Auto Stem Cell Transplant for Lymphoma Patients

Status:
Recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Phase:
Phase 2
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Carmustine
Cyclophosphamide
Cytarabine
Etoposide
Etoposide phosphate
Melphalan